These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23878231)

  • 1. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.
    Pace CS; Song R; Ochsenbauer C; Andrews CD; Franco D; Yu J; Oren DA; Seaman MS; Ho DD
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13540-5. PubMed ID: 23878231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
    Moshoette T; Ali SA; Papathanasopoulos MA; Killick MA
    Retrovirology; 2019 Nov; 16(1):31. PubMed ID: 31703699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.
    Sun M; Pace CS; Yao X; Yu F; Padte NN; Huang Y; Seaman MS; Li Q; Ho DD
    J Acquir Immune Defic Syndr; 2014 Aug; 66(5):473-83. PubMed ID: 24853313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.
    Song R; Pace C; Seaman MS; Fang Q; Sun M; Andrews CD; Wu A; Padte NN; Ho DD
    J Acquir Immune Defic Syndr; 2016 Dec; 73(4):365-373. PubMed ID: 27792681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.
    Moshoette T; Papathanasopoulos MA; Killick MA
    Virol J; 2022 Sep; 19(1):143. PubMed ID: 36071449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
    Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
    PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
    Morgand M; Bouvin-Pley M; Plantier JC; Moreau A; Alessandri E; Simon F; Pace CS; Pancera M; Ho DD; Poignard P; Bjorkman PJ; Mouquet H; Nussenzweig MC; Kwong PD; Baty D; Chames P; Braibant M; Barin F
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):237-45. PubMed ID: 26413851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV: Efficacy through BibNAbs.
    Flemming A
    Nat Rev Drug Discov; 2013 Sep; 12(9):666. PubMed ID: 23989794
    [No Abstract]   [Full Text] [Related]  

  • 9. Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1.
    Li S; Qiao Y; Jiang S; Wang B; Kong W; Shan Y
    J Control Release; 2021 Oct; 338():633-643. PubMed ID: 34509584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.
    Asokan M; Rudicell RS; Louder M; McKee K; O'Dell S; Stewart-Jones G; Wang K; Xu L; Chen X; Choe M; Chuang G; Georgiev IS; Joyce MG; Kirys T; Ko S; Pegu A; Shi W; Todd JP; Yang Z; Bailer RT; Rao S; Kwong PD; Nabel GJ; Mascola JR
    J Virol; 2015 Dec; 89(24):12501-12. PubMed ID: 26446600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
    Tolbert WD; Nguyen DN; Tehrani ZR; Sajadi MM; Pazgier M
    mBio; 2021 Aug; 12(4):e0127421. PubMed ID: 34281393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
    Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.
    Barbian HJ; Decker JM; Bibollet-Ruche F; Galimidi RP; West AP; Learn GH; Parrish NF; Iyer SS; Li Y; Pace CS; Song R; Huang Y; Denny TN; Mouquet H; Martin L; Acharya P; Zhang B; Kwong PD; Mascola JR; Verrips CT; Strokappe NM; Rutten L; McCoy LE; Weiss RA; Brown CS; Jackson R; Silvestri G; Connors M; Burton DR; Shaw GM; Nussenzweig MC; Bjorkman PJ; Ho DD; Farzan M; Hahn BH
    mBio; 2015 Apr; 6(2):. PubMed ID: 25900654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.